ArticleAdvanced healthcare materials2026
Shellac-Mediated Assembly of Nanoparticles for mRNA Delivery.
Article in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Cationic polymers have been extensively explored for messenger RNA (mRNA) delivery owing to their ability to condense nucleic acids and facilitate cellular uptake. High-molecular-weight polymers typically achieve high transfection efficiency but exhibit substantial cytotoxicity, whereas low-molecular-weight polymers show reduced cytotoxicity but low transfection efficiency. To address the tradeoff between toxicity and transfection efficiency, herein, we present a simple and versatile shellac (SL)-mediated assembly strategy, whereby mRNA is complexed with low-molecular-weight cationic polymers (e.g., polyethyleneimine) and subsequently stabilized by SL to form nanoparticles under mild conditions. The SL-based nanoparticles exhibit >90% mRNA encapsulation efficiency and enable mRNA transfection across various cell types while showing negligible cytotoxicity. Furthermore, the SL-based nanoparticle platform enables protein expression and gene editing in mice through both intravenous and oral administration routes. This work highlights the potential of SL as a key building block to direct the assembly and delivery of mRNA, enabling the rational design of modular and versatile nucleic acid delivery platforms for diverse biological applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.